{"preliminary_commentary":{"by_channel":{"x_thread":15,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02525757\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["atezolizumab","carboplatin","paclitaxel"]],"indication":"unresectable non-small cell lung cancer","name":"DETERRED","nct_id":"NCT02525757","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=deterred-nct02525757. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants receive standard chemotherapy and radiation for 6-7 weeks, followed by a 3-4 week rest period when they receive no chemotherapy or radiation.\n\nConsolidation Phase: After the rest period, participants receive MPDL3280A in addition to chemotherapy for 2 cycles.\n\nMaintenance Phase: After completing the consolidation period, participants continue to receive MPDL3280A alone for up to 1 year.","label":"Group 1: Chemotherapy + Radiation","type":"EXPERIMENTAL"},{"description":"Participants receive MPDL3280A, standard chemotherapy, and radiation therapy for 6-7 weeks. This will be followed by a rest period of 3-4 weeks, during which time participant receives 1 dose of MPDL3280A but no chemotherapy or radiation.\n\nConsolidation Phase: After the rest period, participants receive MPDL3280A in addition to chemotherapy for 2 cycles.\n\nMaintenance Phase: After completing the consolidation period, participants continue to receive MPDL3280A alone for up to 1 year.","label":"Group 2: MPDL3280A + Chemotherapy + Radiation","type":"EXPERIMENTAL"}],"collaborators":["Genentech, Inc."],"completion_date":{"date":"2028-01-31","type":"ESTIMATED"},"conditions":["Lung Cancer","Non-Small Cell Lung Cancer"],"enrollment":{"count":52,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"MPDL3280A","otherNames":[],"type":"DRUG"},{"name":"Carboplatin","otherNames":["Paraplatin"],"type":"DRUG"},{"name":"Paclitaxel","otherNames":["Taxol"],"type":"DRUG"},{"name":"Radiation Therapy","otherNames":["XRT"],"type":"RADIATION"}],"last_update":"2026-07-16","lead_sponsor":"M.D. Anderson Cancer Center","official_title":"DETERRED: PD-L1 blockadE To Evaluate the Safety of Lung CanceR Therapy Using Carboplatin, Paclitaxel, and Radiation CombinEd With MPDL3280A","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2028-01-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Time to Toxicity","timeFrame":"15 weeks"}],"references":[{"citation":"Augustyn A, Adams DL, He J, Qiao Y, Verma V, Liao Z, Tang CM, Heymach JV, Tsao AS, Lin SH. Giant Circulating Cancer-Associated Macrophage-Like Cells Are Associated With Disease Recurrence and Survival in Non-Small-Cell Lung Cancer Treated With Chemoradiation and Atezolizumab. Clin Lung Cancer. 2021 May;22(3):e451-e465. doi: 10.1016/j.cllc.2020.06.016. Epub 2020 Jun 20.","pmid":"32798130","type":"DERIVED"}],"start_date":{"date":"2016-01-26","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"MPDL3280A With Chemoradiation for Lung Cancer","url":"https://clinicaltrials.gov/study/NCT02525757"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/deterred-nct02525757"}